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Objectives: Many obesity-associated diseases require intensive medical treat-
ment and are cause of a large proportion of health-related expenditures in 
Germany. Treatment of obesity includes nutritional, exercise and behavior ther-
apy, usually in combination. The goal of behavior therapy for obesity is to bring 
about a long-term alteration in eating and exercise habits of overweight and obese 
individuals. Depending of the severity of obesity, drug treatment may be indi-
cated. To evaluate the clinical and economic effectiveness of behaviour therapy 
for obesity considering approved drugs reducing weight, a Health Technology 
Assessment was carried out in the year 2008. This HTA was updated with publi-
cations up to 12/2013, along with new developments in behavior therapies and 
drugs. MethOds: A systematic review was carried out using relevant electronic 
literature databases Publications chosen according to predefined criteria were 
evaluated by approved methodological standards of evidence-based medicine and 
health economics systematically and qualitatively. Results: Nine randomized 
controlled trials showed moderate but statistically significant reduction of weight 
in the intervention groups compared to control groups between 1.1 kg (at month 4) 
and 6.6 kg (at month 9). Studies with several examination time points resulted in 
statistically significant differences in the first evaluation time point (month 6) but 
not in the subsequent time points (month 12, 18, 24). The most frequent approach 
used for behavior therapy, was per phone or Email, two studies offered behavior 
therapy face-to-face. New behavior therapy approaches applied were techniques 
such as “Motivational Interviewing” and “Transtheoretical model”. No study was 
identified examining behavior therapy in combination with approved drug therapy. 
Two identified studies evaluating cost-effectiveness of behavior therapy per Email 
or phone showed cost-effectiveness for this kind of intervention but the results are 
biased due to a high rate of drop-outs. cOnclusiOns: Behavior therapy consider-
ing new approaches is an effective method to reduce weight.
PSY119
ComPariSon of TreaTmenT PaTTernS and diSeaSe SeveriTY among 
PaTienTS WiTh PSoriaTiC arThriTiS (PSa) reCeiving Their firST BiologiC, 
TreaTed BY rheumaTologiSTS and dermaTologiSTS in euroPe (eu)
Narayanan S.1, Hautamaki E.1, Lu Y.2, Franceschetti A.2
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To compare rheumatologists and dermatologists in terms of treat-
ment patterns and disease severity among PsA patients receiving their first bio-
logic in 5EU (UK/Germany/France/Italy/Spain). MethOds: A medical chart-review 
study of psoriasis and PsA patients was conducted among rheumatologists and 
dermatologists in hospitals and private practices to collect de-identified data on 
disease and treatment characteristics. Physicians were screened for duration of 
practice (3-30yrs) and patient volume (≥ 2 Psoriasis/PsA biologic patients/month) 
and recruited from a large panel to be geographically representative in each country. 
Physicians abstracted charts of the next 5 consecutive Psoriasis/PsA patients in 
their respective sites. Treatment patterns and disease severity among PsA patients 
on their first line of biologic therapy treated by rheumatologists and dermatolo-
gists respectively were compared using descriptive statistics. Results: In Q42012, 
337 rheumatologists abstracted 527 PsA patient-charts (mean-age: 47.4yrs, male: 
51.4%) and 225 dermatologists abstracted charts of 109 psoriasis patients with PsA 
(mean-age: 49.0yrs, male: 56.0%; 55.1% were managed in conjunction with a rheu-
matologist; 67% were referred by GP/another dermatologist). Time to first biologic 
since diagnosis was 41.0mo/20.8mo for the rheumatologist/dermatologist-treated 
cohorts; disease severity at biologic initiation per physician judgment was (mild/
moderate/severe): rheumatologist-treated-cohort: 2.7%/60.2%/37.2%, dermatologist-
treated-cohort: 1.96%/46.08%/ 51.96%. In rheumatologist-treated-cohort: treatment 
naïve-12.9%, non-biological DMARDS-experienced: 74.0%; in dermatologist-treated 
cohort: treatment nainve-6.5%, 1-or-2 systemic-treatment-experienced prior to their 
first biologic-initiation: 69.5%. 38.7%/61.3% and 27.5%/72.5% had moderate-severe/
remission-mild disease-status among rheumatologist- and dermatologist-treated 
cohort respectively. Average current PASI score was higher among rheumatologist-
treated-cohort (18.7 vs. 10.3). cOnclusiOns: Across the EU5, PsA treatment pat-
terns and disease severity varied based on physician specialty (rheumatologist vs. 
dermatologist); at biologic initiation dermatologists reported a significantly higher 
proportion of moderate/severe PsA patients than rheumatologists, but once first 
biologic treatment was well established dermatologists reported a lower disease 
burden then rheumatologists. Factors influencing these observed variations, includ-
ing optimal therapeutic approaches and care coordination between specialties to 
alleviate patient burden may warrant further scrutiny.
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Objectives: To assess treatment patterns and disease severity of psoriasis patients 
receiving their first biologic-therapy in EU. MethOds: A medical chart-review study 
of psoriasis patients was conducted in 4Q2013 in EU5 (UK/Germany/France/Italy/
Spain) among dermatologists to collect de-identified data on disease/treatment 
characteristics. Physicians were screened for duration-of-practice (3-30yrs) and 
patient-volume (≥ 2psoriasis biologic patients/month) and recruited from a large 
panel to be geographically representative in each country. Physicians abstracted the 
charts of next 5 consecutive psoriasis patients in their center/practice. Results from 
patients on their first biologic treatment were analyzed and comparisons made to 
EU5-averages. Results: 877 patient-charts were abstracted; 702 (80.0%) were on 
their first biologic (mean age: 47.3yrs, male: 64.1%). Prior to initiating biologic ther-
apy, immunomodulators/phototherapy were more widely used in UK than in other 
countries (90.3%/43.1% vs. 76.6%/30.4% overall, respectively); in Germany, fumarates/
Objectives: Reimbursement decisions are often unsystematic and lack transpar-
ency, especially for orphan drugs. The objective of this study was to demonstrate 
whether multi-criteria decision analysis (MCDA) can support rational and explicit 
reimbursement decision process for orphan drugs in the Netherlands. MethOds: 
An Analytic Hierarchy Process (AHP) framework was used in which Health Economics 
students were asked to weigh criteria used in drug reimbursement decisions through 
a web-based survey. Criteria were identified by a systematic literature review. Three 
different orphan drugs (alglucosidase alfa in infantile Pompe disease, canakinumab in 
cryopyrin-associated periodic syndromes and investigational product in rare disease) 
were also assessed by the students on their performance on these criteria. Criteria 
weights and performance scores were aggregated to an overall score for each orphan 
drug. Rank-ordering on overall scores prioritized the reimbursement of the three 
drugs. The students were also asked to assess the AHP survey on feasibility. Results: 
Nine criteria were identified and categorized in four domains; disease (burden of ill-
ness without treatment, life-threatening nature of the disease), drug (availability of 
other treatments, effectiveness of the drug, side effects and safety of the drug), finan-
cial aspects (annual costs of the drug per patient, budget impact, cost-effectiveness) 
and quality of evidence. The criterion ‘life-threatening nature of the disease’ was 
given the highest importance weight and budget impact the least. Alglucosidase alfa 
for treatment of infantile Pompe disease ranked highest of the three orphan drugs 
examined, particularly due to its performance in the disease and drug domains. The 
AHP survey was perceived as difficult by the respondents, which was confirmed by 
poor values for consistency ratios. cOnclusiOns: Performing MCDA can enable 
explicit, transparent and auditable reimbursement decision-making for orphan drugs. 
However, its feasibility and applicability needs further investigation.
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Objectives: To look at the affordability of orphan medications across Europe and 
whether payer attitudes to high-price medications are changing in the face of rising 
health care expenditure and tighter budgets. MethOds: We conducted an online 
semi-quantitative survey of 10 European markets and the USA to understand how 
payers views and attitudes are changing in response to new treatments coming to 
market for rare and ultra-rare conditions. The payers selected for the survey hold 
or have held senior positions within their respective market institutions. The USA 
was included to provide international context to the European results. Results: 
82% of payers surveyed believe that the current approach to orphan drug pricing is 
unsustainable in the future and all respondents predict a tougher approach from 
payers going forward. 73% of payers do not believe that patent expiry alone will free 
up the necessary space for innovative orphan and ultra-orphan products. 82% of the 
payers surveyed believed that less than half of all orphan and ultra-orphan drugs 
coming to market are supported by an adequate evidence base for reimbursement. 
Although payers view rare diseases as a relatively high priority to fund, they are still 
behind therapy areas such as oncology and cardiovascular disease. cOnclusiOns: 
As the financial performance of European countries begins to diverge, so do atti-
tudes towards the funding of orphan medicines. The increasing number of rare 
diseases is forcing payers to view orphan drugs in a new light and they are becom-
ing increasingly sceptical about the prices charged in relation to the clinical benefit 
offered. There is space for innovation; and patent expiry is freeing up funds, but rare 
diseases are competing with other therapy areas for limited budget. The bottom-line 
is that as rare disease spending becomes a higher proportion of pharmaceutical 
budgets, payers will take action to curb this trend.
PSY117
SourCeS of informaTion and PharmaCiSTS’ KnoWledge regarding 
rare diSeaSeS and orPhan drugS: CroSS-SeCTional STudY in SerBia
Arsic J.1, Krajnovic D.2, Tasic L.2, Marinkovic V.2, Djordjevic J.3
1Pharmacy Vranje, Vranje, Serbia and Montenegro, 2University of Belgrade – Faculty of Pharmacy, 
Belgrade, Serbia and Montenegro, 3Alvogen Pharma d. o. o, Serbia, Belgrade, Serbia and 
Montenegro
Objectives: The lack of information and scientific knowledge of rare diseases (RDs) 
and orphan drug (ODs) could affect the quality of health care delivered to patients suf-
fering from rare diseases. The aim of this study was evaluation of the level of the general 
epidemiological knowledge among pharmacists regarding RDs and ODs as well as how 
that knowledge is influenced by information sources, education level and years of expe-
rience. MethOds: The research design was based on a descriptive cross-sectional study. 
A questionnaire previously used in a pilot KAP study in Serbiain2012 was applied. The 
respondents were 182 pharmacists from public pharmacies in seven of 29 districts in 
Serbia. Individual level of knowledge was assessed by total number of correct answers 
from a maximum of 9, and overall knowledge was an average of the individual level of 
knowledge. Results: In total, 155 pharmacists were included in the full analysis set 
(response rate was 86.3%). Overall, the mean age was 43.4 years, and 94% were women. 
The average number of information sources regarding RD was 1.7%, and mostly one 
source out of five was used (56.1%). Pharmacists who were engaged in post-graduate 
programmes or completed such programmes tended to use more sources of information 
(69.2%) than those who were not involved in any such programme (41.9%). The mean 
value of correct answers about pharmacists’ knowledge regarding RD and OD was 4 ± 
1.77. Most pharmacists (n = 30, 19.35%) replied correctly to 6 questions. cOnclusiOns: 
The results indicate that years of experience and age among pharmacists do not have 
influence to the overall knowledge about RD. The positive impact of education was evi-
dently, and for the better pharmaceutical care of RD patients the training of pharmacists 
to proper use of professional sources of information should be usefully.
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